The 2020 CIPA Life Sciences Webinar Series

Tuesday 17th November 2020

Topic: Hot Topics in Life Sciences IP and SPCs Case law update

Date: Tuesday 17th November, 2020

Time: 12:00 - 1:15pm GMT

Agenda to Include:

Panel discussion on the issues of focus for small and large companies in the life sciences industry.

• Brexit

• Covid implications

Case law update on SPCs

Speakers:

Susan Chiappinelli, GlaxoSmithKline

Susan Chiappinelli started at GSK as a patent trainee in 1998.  Since then she has managed IP in a range of areas including large and small molecule and cell and gene therapies, vaccines and general tech such as gene editing and AI.  She is usually based in Stevenage at GSK’s UK R&D hub, leading a team of UK and US patent attorneys who provide IP support to all stages of the GSK pharma pipeline from early target validation through to patent expiry and beyond. 

Sally Curran, AstraZeneca

Sally is a member of the AstraZeneca IP Leadership Team and leads a team supporting their Respiratory & Immunology (R&I) therapy area.  Her experience at AstraZeneca covers IP strategy across the entire spectrum of research, development and commercialisation.  In addition to leading a team handling global patent procurement Sally manages IP portfolios for major on-market products and has also been involved in significant in-licences and acquisitions in the R&I therapy area.  Sally was also instrumental in defining AstraZeneca’s IP strategy for open innovation activities via its Open Innovation portal (www.openinnovation.astrazeneca.com).  She is heavily involved in people development activities across AstraZeneca’s Legal department as a whole, and is active in Inclusion & Diversity and mentoring initiatives within the company and in the broader Cambridge area.  Prior to joining AstraZeneca in 2010 Sally spent more than a decade in private practice IP firms.

Rob Stephen, CMS

Robert is a Chartered Patent Attorney and European Patent Attorney with over 20 years' experience. He has a PhD in molecular genetics and his practice focusses on biotechnology and pharmaceuticals.  He is a co-founder of the SPC blog and leads the patent attorney team at CMS, as well as being the co-chair of the CMS life science practice in the UK

Gareth Morgan, CMS

Gareth’s litigation practice has a particular focus in the Life Sciences and Healthcare sector. Gareth has acted in many landmark UK IP trials concerning patent entitlement, biotechnology patent validity and infringement, SPCs (including EU Court of Justice references) and the interpretation of IP licences. In addition, Gareth represents clients in judicial review proceedings concerning medicinal product marketing authorisations. He regularly advises life sciences companies on the judicial review of medicines agency decisions before the EU General Court and Court of Justice in Luxembourg and national Member State courts in the EU, often combining such actions with coordinated multi-jurisdictional patent litigation concerning the same product.

In his advisory practice Gareth has assisted pharmaceutical and biotechnology clients on aspects of orphan exclusivity, paediatric exclusivity, biosimilar applications, centralised procedure applications, CHMP referral procedures and, interpretation of the medicines directives and associated guidance. He also provides legal and technical advice concerning CHM appeals, scientific advice meetings, CHMP oral explanation meetings and, CHMP referrals.

Moderator:

Marion Rees, Adiga Life Sciences 

Marion is a Chartered Patent Attorney and European Patent Attorney with 20 years’ experience working in-house for small and large life science companies including GSK, Oxford Nanopore Technologies and Circassia. She is a member of the CIPA Life Sciences Committee and has for several years been part of the organising committee for the annual CIPA Life Sciences conference. She is currently VP of Intellectual Property and Legal Affairs at Adiga Life Sciences in Oxford.

Previous Day                              Next Day